[
  {
    "info": {
      "NCT": "NCT05092360",
      "Protocol_No": "Alkermes_ALKS 4230-007 GOG-3063 ENGOT-ov68 (ARTISTRY-7)",
      "jit": "Avera Trials",
      "trial_name": "ARTISTRY-7"
    },
    "disease": {
      "summary": "Epithelial Ovarian Cancer, Platinum-resistant Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer",
      "details": [
        {
          "code": "Cervical Clear Cell Carcinoma (CECC)",
          "selection": "include",
          "stage": "Stage III;Recurrent"
        },
        {
          "code": "Cervical Endometrioid Carcinoma (CEEN)",
          "selection": "include",
          "stage": "Stage III;Recurrent"
        },
        {
          "code": "Clear Cell Borderline Ovarian Tumor (CCBOV)",
          "selection": "include",
          "stage": "Stage III;Recurrent"
        },
        {
          "code": "Endometrioid Ovarian Cancer (EOV)",
          "selection": "include",
          "stage": "Stage III;Recurrent"
        },
        {
          "code": "High-Grade Serous Fallopian Tube Cancer (HGSFT)",
          "selection": "include",
          "stage": "Stage III;Recurrent"
        },
        {
          "code": "High-Grade Serous Ovarian Cancer (HGSOC)",
          "selection": "include",
          "stage": "Stage III;Recurrent"
        },
        {
          "code": "Ovarian Epithelial Tumor (OVT)",
          "selection": "include",
          "stage": "Stage III;Recurrent"
        },
        {
          "code": "Peritoneal Mesothelioma (PEMESO)",
          "selection": "include",
          "stage": "Stage III;Recurrent"
        },
        {
          "code": "Peritoneal Serous Carcinoma (PSEC)",
          "selection": "include",
          "stage": "Stage III;Recurrent"
        }
      ]
    },
    "query": {
      "nct": "NCT05092360",
      "title": "Phase 3 Study of Nemvaleukin Alfa in Combination With Pembrolizumab in Patients With Platinum-Resistant Epithelial Ovarian Cancer (ARTISTRY-7)",
      "current_status": "Recruiting",
      "status_verif_date": "May 2023",
      "last_update_date": "May 2, 2023",
      "trial_hold_status": "open",
      "sponsor": "Alkermes, Inc.",
      "brief_summary": "This is a Phase 3, multicenter, open-label, randomized study of nemvaleukin in combination with pembrolizumab versus protocol-specific Investigator's choice chemotherapy in patients with platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer.",
      "conditions": "Platinum-resistant Ovarian Cancer | Fallopian Tube Cancer | Primary Peritoneal Cancer",
      "type": "Interventional",
      "phase": "Phase 3",
      "arm": [
        {
          "ArmID": "1",
          "cohortlabel": "Nemvaleukin and Pembrolizumab Combination",
          "drug": "Nemvaleukin and Pembrolizumab Combination | NA | NA | NA",
          "arm_type": "Experimental",
          "line_of_therapy": "3",
          "arm_hold_status": "Not available",
          "biomarker": [
            {
              "cohort": "Nemvaleukin and Pembrolizumab Combination",
              "Gene": "Not available",
              "Gene2": "Not available",
              "Type": "Not available",
              "Variant": "Not available",
              "Selection": "include",
              "Function": "Not available",
              "summary": "absent"
            }
          ]
        },
        {
          "ArmID": "2",
          "cohortlabel": "Pembrolizumab",
          "drug": "Pembrolizumab | NA | NA | NA",
          "arm_type": "Experimental",
          "line_of_therapy": "3",
          "arm_hold_status": "Not available",
          "biomarker": [
            {
              "cohort": "Pembrolizumab",
              "Gene": "Not available",
              "Gene2": "Not available",
              "Type": "Not available",
              "Variant": "Not available",
              "Selection": "include",
              "Function": "Not available",
              "summary": "absent"
            }
          ]
        },
        {
          "ArmID": "3",
          "cohortlabel": "Nemvaleukin",
          "drug": "Nemvaleukin | NA | NA | NA",
          "arm_type": "Experimental",
          "line_of_therapy": "3",
          "arm_hold_status": "Not available",
          "biomarker": [
            {
              "cohort": "Nemvaleukin",
              "Gene": "Not available",
              "Gene2": "Not available",
              "Type": "Not available",
              "Variant": "Not available",
              "Selection": "include",
              "Function": "Not available",
              "summary": "absent"
            }
          ]
        },
        {
          "ArmID": "4",
          "cohortlabel": "Investigator's Choice",
          "drug": "Pegylated Liposomal Doxorubicin (PLD) | Paclitaxel | Topotecan | Gemcitabine",
          "arm_type": "Active Comparator",
          "line_of_therapy": "3",
          "arm_hold_status": "Not available",
          "biomarker": [
            {
              "cohort": "Investigator's Choice",
              "Gene": "Not available",
              "Gene2": "Not available",
              "Type": "Not available",
              "Variant": "Not available",
              "Selection": "include",
              "Function": "Not available",
              "summary": "absent"
            }
          ]
        }
      ],
      "docs": "<a href=\"https://avera-ereg-prod.forteresearchapps.com/ereg-web/protocols/2062/section-4657\" target=\"_blank\">eREG<\/a>",
      "doclastupdate": "2023-05-11",
      "locations": "Sioux Falls SD",
      "min_age": "18 Years",
      "gender": "Female",
      "link": "<a href=\"https://clinicaltrials.gov/ct2/show/NCT05092360\" target=\"_blank\">NCT05092360<\/a>"
    }
  }
]
